<?xml version="1.0"?>
<rss version="2.0">
	<channel>
		<title>Drug News in Central Nervous System area.</title>
		<link>http://www.lifescience-online.com/</link>
		<description>News Feed Powered by Lifescience-online.com</description>
		<language>en-us</language>
		<pubDate>Wed, 07 Jan 2009 15:14:05 +0100</pubDate>
		<lastBuildDate>Wed, 07 Jan 2009 15:14:05 +0100</lastBuildDate>
		<category>News</category>		

		<image>
			<title>Lifescience-online</title>
			<url>http://rss.lifescience-online.com/images/logo.gif</url>
			<link>http://www.lifescience-online.com/</link>
			<width></width>
			<height></height>
			<description>Lifescience-online</description>
		</image>

		<item>
			<title>Orexigen Therapeutics, Inc. (OREX) Issued a Key Fourth U.S. Patent on Contrave(R)</title>
			<link>http://www.lifescience-online.com/Orexigen_Therapeutics__Inc___OREX__Issued_a_Key_Fo,13633.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/4/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Central Nervous System</dd><br /><dt><b>Category</b> :</dt><dd>Partnerships and Licensing</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/orexigen_therapeutics,9573.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>OREXIGEN THERAPEUTICS INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/NALTREXONE_SR_+_BUPROPION_SR,21615.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>NALTREXONE SR + BUPROPION SR</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 04 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>AstraZeneca Receives FDA Complete Response Letter on Seroquel XR for Major Depressive Disorder</title>
			<link>http://www.lifescience-online.com/AstraZeneca_Receives_FDA_Complete_Response_Letter_,13496.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/2.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Central Nervous System</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/astrazeneca,339.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>ASTRAZENECA PLC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/QUETIAPINE_FUMARATE,956.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>QUETIAPINE FUMARATE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Wed, 24 Dec 2008 11:04:26 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Memory Pharmaceuticals Initiates Biomarker Study of R3487/MEM 3454 in Schizophrenia</title>
			<link>http://www.lifescience-online.com/Memory_Pharmaceuticals_Initiates_Biomarker_Study_o,13545.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/3.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Central Nervous System</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/memory_pharmaceuticals,6104.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>Memory Pharmaceuticals Corp</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/MEM-3454,21083.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>MEM-3454</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Tue, 23 Dec 2008 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Teva Announces Tentative Approval of Generic Seroquel(R) Tablets</title>
			<link>http://www.lifescience-online.com/Teva_Announces_Tentative_Approval_of_Generic_Seroq,13567.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/2.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Central Nervous System</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/teva_pharmaceutical_industries,1189.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>TEVA PHARMACEUTICAL INDUSTRIES LTD</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/QUETIAPINE_FUMARATE,956.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>QUETIAPINE FUMARATE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 22 Dec 2008 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Nabi Biopharmaceuticals Reaches Special Protocol Agreement With FDA for NicVAX(r) Phase 3 Trial Protocol</title>
			<link>http://www.lifescience-online.com/Nabi_Biopharmaceuticals_Reaches_Special_Protocol_A,13525.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Central Nervous System</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/nabi_biopharmaceuticals,918.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>NABI BIOPHARMACEUTICALS</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/NICVAX,5498.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>NICVAX</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 22 Dec 2008 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>NovaDel Pharma (NVD) Receives FDA Approval of Zolpimist</title>
			<link>http://www.lifescience-online.com/NovaDel_Pharma__NVD__Receives_FDA_Approval_of_Zolp,13488.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/3.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Central Nervous System</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/novadel_pharma,6274.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>NOVADEL PHARMA INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/ZOLPIDEM_(SUBLINGUAL),757.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>ZOLPIDEM (SUBLINGUAL)</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 21 Dec 2008 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Newron Pharmaceuticals To Initiate Phase IIb/III Study Of Ralfinamide In Patients With Neuropathic Low Back Pain (NLBP)</title>
			<link>http://www.lifescience-online.com/Newron_Pharmaceuticals_To_Initiate_Phase_IIb_III_S,13508.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/3.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Central Nervous System</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/newron_pharmaceuticals_spa,6236.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>NEWRON PHARMACEUTICALS SPA</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/RALFINAMIDE,5812.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>RALFINAMIDE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 21 Dec 2008 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>ProStrakan Group and Paladin Labs Inc. (CC:PLB) Complete Agreement for Abstral(R) and Sancuso(R)</title>
			<link>http://www.lifescience-online.com/ProStrakan_Group_and_Paladin_Labs_Inc___CC_PLB__Co,13512.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/4/0.gif' /></div><dl><dt><b>Category</b> :</dt><dd>Partnerships and Licensing</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/paladin_labs,9008.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>PALADIN LABS INC</u></font></a><br /><a href='http://www.lifescience-online.com/prostrakan_group,9119.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>PROSTRAKAN GROUP LTD</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/GRANISETRON_TRANSDERMAL_DELIVERY_SYSTEM,8104.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>GRANISETRON TRANSDERMAL DELIVERY SYSTEM</u></font></a><br /><a href='http://www.lifescience-online.com/FENTANYL_BUCCAL_TABLET,24182.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>FENTANYL BUCCAL TABLET</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 21 Dec 2008 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

	</channel>
</rss>